We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

Saving the Planet - and Preventing Myeloma
Research has indicated a clear link between toxic chemical exposure and myeloma, and the number of new myeloma cases is on the rise. Some chemicals have been tested, but others that may have links to cancer have not been thoroughly investigated. In his blog this week, IMF Chairman Dr. Brian Durie questions why there is not a greater focus on chemical exposure, and calls on the myeloma community to rally in an effort to decontaminate our planet and the people on it.

Measles Virotherapy for Myeloma: New Clinical Trial
Earlier this year, the Mayo Clinic shared exciting results from a clinical trial conducted by Dr. Stephen Russell and his team to test engineered measles virus in myeloma patients. Dr. Russell discussed the approach during the International Myeloma Working Group Conference Series Debate in June. The Mayo Clinic is now enrolling patients in a second clinical trial.

Missed our Sept. 10 briefing on Capitol Hill? Watch the replay here.
The IMF hosted a successful briefing in Washington, DC called Understanding Environmental Exposures and Cancer: The Case of Multiple Myeloma. The briefing was attended by congressional staff, patient advocacy partners, and myeloma patients. Speakers including Dr. Ola Landgren, Dr. Laura Crowley, and myeloma patient and 9/11 volunteer Patricia Workman highlighted the ongoing health concerns facing first responders and volunteers who risked their lives in the aftermath of the attacks on 9/11, as well as other environmental factors that show a marked increase in myeloma rates over time.

9/11 Health Program Guides
On September 10, 2014 the IMF hosted a successful briefing in Washington, DC called Understanding Environmental Exposures and Cancer: The Case of Multiple Myeloma. The briefing was attended by congressional staff, patient advocacy partners, and myeloma patients. Speakers including Dr. Ola Landgren, Dr. Laura Crowley, and myeloma patient and 9/11 volunteer Patricia Workman highlighted the ongoing health concerns facing first responders and volunteers who risked their lives in the aftermath of the attacks on 9/11, as well as other environmental factors that show a marked increase in myeloma rates over time.

The briefing, along with the messages of support we received from the larger patient community, exposed the need for further assistance to those who might have health concerns in the wake of this national tragedy. Because of those concerns and obvious need, we have created two guides to assist those who were exposed to the hazards at Ground Zero. The guides pertain to the two programs; the World Trade Center Health Program and the September 11th Victim Compensation Fund.


Becoming a Patient Advocate
A special blog post from myeloma patient Cynthia Chmielewski details her involvement in various aspects of patient advocacy, including her work as a support advocate, political advocate, and research advocate. Cynthia shares how her thirst for knowledge about myeloma following her diagnosis led her to advocacy. She writes, “I have evolved as a patient and an advocate over the last six years and I have to credit the IMF with being instrumental in my metamorphosis.”

Should Myeloma Treatment Be Fully Personalized?
Personalized treatment may be a hot topic, but in his blog this week, IMF Chairman Dr. Brian Durie explains why a broader approach to myeloma treatment should lead to the best outcomes for myeloma patients and ultimately a cure for myeloma. This concept is an important aspect of the IMF’s Black Swan Research Initiative®. Dr. Durie explains, “the goal is to have broadly applicable therapy and learn more from treating larger numbers of patients together, not separately.”

Myeloma Support Group in India Wins UNESCO Award
Yoddhas, the first Yoddhas, the first myeloma support group in India, founded by 29-year-old myeloma patient Rahul Yadav, won the People’s Choice Award for best project in the global Youth Citizenship Entrepreneurship Competition. The competition was sponsored by UNESCO, the United Nations Organization for Education, Science and Culture. Congratulations Rahul and Yoddhas! CLICK HERE to learn more about Yoddhas, which means “warrior” in Hindi, and CLICK HERE to learn more about the award.myeloma support group in India, founded by 29-year-old myeloma patient Rahul Yadav, won the People’s Choice Award for best project in the global Youth Citizenship Entrepreneurship Competition. The competition was sponsored by UNESCO, the United Nations Organization for Education, Science and Culture. Congratulations Rahul and Yoddhas! CLICK HERE to learn more about Yoddhas, which means “warrior” in Hindi, and CLICK HERE to learn more about the award.

International Myeloma Foundation Hosts Congressional Briefing on Environmental Exposures
The International Myeloma Foundation is hosting a briefing to discuss research on links between exposure to environmental factors and multiple myeloma. Speakers at the briefing will discuss the latest research findings and share their personal stories about their experience with multiple myeloma. The audience will learn about multiple myeloma, opportunities to further research, potential environmental risk factors for multiple myeloma, and efforts among patient advocates, industry, researchers and policy makers to reduce the exposure to environmental toxins associated with myeloma.

Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
The New England Journal of Medicine published a study this week showing that Revlimid (lenalidomide) plus low-dose dexamethasone improves survival and other measures of efficacy compared to MPT (melphalan, prednisone, and thalidomide) in newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also showed that continuing use of Revlimid-dexamethasone instead of stopping after a fixed number of treatments provided further advantages in multiple measures

Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma teleconference
The IMF's popular Living Well with Myeloma teleconference series returns on August 28th, with "Understanding the Immune System and Lab Values in Myeloma." The discussion and Q&A will be led by IMF Nurse Leadership Board member Ann McNeill, RN, MSN, APRN-C, Multiple Myeloma Division, Hackensack University Medical Center. The free teleconference will be held on Thursday, August 28th at 7 pm ET/ 4 pm PT.

    next      view all